YL-109

Research use only, not for human use.

YL-109 is a novel anticancer agent which has ability to inhibit breast Y cell growth and invasiveness in vitro and in vivo.

YL-109 is a novel anticancer agent which has ability to inhibit breast Y cell growth and invasiveness in vitro and in vivo.

YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell proliferation, motility, and invasiveness in breast cancer cells.YL-109 (1 μM) increases both CHIP mRNA and protein levels in MDA-MB-231 cells. Cell Proliferation Assay Cell Line:MCF-7 and MDA-MB-231 cellsConcentration:0.001, 0.01, 0.1, 1, 10 μM Incubation Time:96 hours Result:Strongly inhibited cell proliferation of MCF-7 and MDA-MB-231 cells in a dose-dependent manner (IC50=85.8 nM and 4.02 μM, respectively).

YL-109 (15 mg/kg; s.c. for every 2 d) inhibits both tumor growth and cancer metastasis of breast cancer cells in vivo. Animal Model:BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells Dosage:15 mg/kg Administration:S.c. every 2 days for 63 days Result:Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells.

YL109 | YP-109 | YP 109

Endocrinology/Hormones

AhR

AhR

Cancer

——

36341-25-0

257.31

C14H11NO2S

>98% (HPLC)

Soluble in Water

COC1=CC(C2=NC3=CC=CC=C3S2)=CC=C1O

4-(benzo[d]thiazol-2-yl)-2-methoxyphenol

(-20℃)

With Ice Pack

≥ 2 years